Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
35 hedge funds and large institutions have $13M invested in Vincerx Pharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 17 reducing their positions, and 10 closing their positions.
17% less funds holding
Funds holding: 42 → 35 (-7)
30% less capital invested
Capital invested by funds: $18.6M → $13M (-$5.55M)
65% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 17
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.94M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$1.33M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$87.2K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$74.1K |
| 5 |
SRC
Sage Rhino Capital
Menlo Park,
California
|
+$27.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.62M |
| 2 |
Holocene Advisors
New York
|
-$1.05M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$875K |
| 4 |
CC
Clearline Capital
New York
|
-$333K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$284K |
VINC Hedge Fund Activity: Q4 2022 in Review
35 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q4 2022, worth a combined $13M — down 30% from $18.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of VINC and 3 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 6 added.
The largest buyer was Goldman Sachs, adding an estimated $1.94M. The largest seller was Rubric Capital Management (New York), cutting an estimated $1.62M.
- 35 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q4 2022, down from 42 in Q3 2022.
- Funds reported $13M of Vincerx Pharma, Inc. Common Stock stock for Q4 2022, down 30% quarter-over-quarter.
- 3 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of -7 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q4 2022 was Goldman Sachs, an estimated $1.94M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q4 2022 was Rubric Capital Management (New York), an estimated $1.62M sold.
Based on aggregated 13F filings for Q4 2022.